Work

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Year: 2018

Type: article

Study design: Clinical Trial

Source: Clinical Breast Cancer

DOI: 10.1016/j.clbc.2018.09.012

Authors: Peter A. Kaufman, Hans Wildiers, Gilles Freyer, Margaret Kemeny, Anthony Gonçalves, Guy Jerusalem, Alison Stopeck, Nandagopal Vrindavanam, Florence Dalenc, Nuwan Nanayakkara, Benjamin Wu, Cheryl A. Pickett

Institutions: Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, Universitair Ziekenhuis Leuven, KU Leuven, Lyon 1 Université, Hospices Civils de Lyon, Institut Paoli-Calmettes, University of Liège, Centre Hospitalier Universitaire de Liège, Stony Brook University Hospital, Stony Brook Medicine, Institut universitaire du cancer de Toulouse Oncopole, Institut Claudius Regaud, IQVIA (United States), Amgen (United States)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Novartis, Roche, Celgene, Puma Biotechnology, British Microcirculation Society, Daiichi-Sankyo

OpenAlex ID: W2896782066

FWCI: 0.551

Cites: 54

Cited by: 8

Related to: 10